A decade of research and a single federal signature have finally given Florida's citrus industry a tool engineered specifically to fight the disease that nearly destroyed it.
On April 28, 2026, the U.S. Environmental Protection Agency approved CarriCea T1, a CRISPR-edited Carrizo citrange rootstock built to resist Huanglongbing, the bacterial disease known as citrus greening that has wiped out more than 90 percent of Florida's citrus production over the past two decades. EPA Administrator Lee Zeldin called the approval a tool that fights disease at the source while reducing the need for conventional pesticide sprays. For Soil Culture Solutions LLC, the Tampa-based biotech firm doing business as Soilcea, the signature converted a years-long laboratory project into something it can ship to growers this season, with 200,000 trees already moving through the nursery pipeline and customer orders north of 300,000 units before the ink on the registration had even dried.
Citrus greening was first confirmed in Florida in August 2005, carried tree to tree by the Asian citrus psyllid, a vector roughly the size of a grain of rice. The bacterium behind it, Candidatus Liberibacter asiaticus, colonizes the phloem and chokes off a tree's ability to move nutrients and water, leaving fruit small, bitter, and lopsided before the tree itself declines and dies. There is still no cure once a tree is infected.
The production numbers chart the scale of the collapse with brutal precision. Florida orange output has fallen from nearly 292 million boxes in the 2003-04 season to roughly 12.15 million boxes in 2024-25, according to USDA's National Agricultural Statistics Service, a decline of about 95 percent. Yields per acre have dropped from over 400 boxes to roughly 70. Industry and government data tied to the epidemic put the toll at 50 million trees lost, 47,000 jobs gone, and $76.5 billion in cumulative economic damage. The disease has since spread beyond Florida into California, Texas, Alabama, Louisiana, Hawaii, Mississippi, South Carolina, and Georgia, and was confirmed for the first time in Arizona's Nogales area earlier this year.
CarriCea T1 did not arrive from a pesticide chemist's bench. It came out of the lab of Nian Wang, a professor of microbiology and cell science at the University of Florida's Citrus Research and Education Center in Lake Alfred, who has spent two decades mapping how Candidatus Liberibacter asiaticus interacts with citrus tissue. Wang's team used CRISPR to make loss-of-function edits to three citrus genes, ACD2, LLS1, and CP, that the bacterium exploits to establish infection. Rather than introducing a foreign gene, as earlier transgenic approaches to citrus disease resistance had done, the edits disrupt the plant's own susceptibility pathway. Soilcea CEO Yianni Lagos described the underlying logic bluntly: a bacterium's only real objective is to multiply, and in greening that means producing the C-Las protein. The edited rootstock interrupts that protein interaction and lets the tree's existing defenses do the rest.
The product Soilcea actually petitioned to register sits in an unusual regulatory niche. According to the company's EPA submission, the commercial CarriCea T1 line also carries a Neomycin Phosphotransferase II marker, a CRISPR-Cas9 delivery cassette, and Agrobacterium tumefaciens-derived sequences, including a CaMV 35S promoter and nopaline synthase elements, used to insert the editing machinery in the first place. That combination of vector residue is exactly why the U.S. Department of Agriculture's Animal and Plant Health Inspection Service classified CarriCea as a regulated article under 7 CFR part 340 even though the final edited genes carry no foreign DNA in the citrus genome itself. APHIS's draft plant pest risk assessment, opened for public comment through April 13, 2026 under docket APHIS-2025-1067, concluded that the rootstock posed no greater plant pest risk than unmodified Carrizo citrange and cleared it for nonregulated status. The EPA's parallel review treated the cas9 protein and guide RNA sequences as a plant-incorporated protectant, the same regulatory category used for pest-resistance traits, and granted an exemption from a residue tolerance requirement because none of the edited proteins move from rootstock into the fruit-bearing scion.
The approval almost slipped past its own deadline. As recently as November 2025, a federal government shutdown stalled the review process at exactly the moment growers could least afford delay. Rick Dantzler, chief operating officer of the Citrus Research and Development Foundation, wrote during the public comment period that grower sentiment across Florida was enthusiastic and that support for the rootstock was widespread, while warning that growers were nearly out of time and money. Lagos, in an interview in late April just before the registration came through, said the company's environmental and human health risk assessments had come back clean, with no reasonable risks detected, and that approval was expected any day. Eighteen months earlier, he had been telling reporters the first commercial trees might not be ready until the end of 2026 or spring 2027. The EPA's signature compressed that timeline by roughly a season, landing just ahead of the 2026-27 planting window that growers needed to hit to keep multi-year replanting cycles on schedule, since citrus trees take three years to begin fruiting and four to reach meaningful production.
Florida Citrus Mutual, the state's principal grower association, did not undersell the moment. Board President Kevin Koppelman called the rootstock the first look at the citrus trees of the future, and EVP and CEO Matt Joyner said the approval has the potential to transform the global citrus industry, not just Florida's. The framing matters because Florida's brand as the nation's citrus capital has been quietly slipping for years; the registration gives growers, lenders, and crop insurers their first concrete data point that the decline curve might finally bend.
What separates CarriCea T1 from a one-off scientific press release is that Soilcea is already building a second product line behind it, segmented by soil chemistry rather than geography alone. Carrizo, the rootstock CarriCea T1 is built on, is the most widely planted rootstock in American citrus, but it is not universally well suited to Florida's terrain. According to University of Florida's own rootstock guidance, Carrizo performs poorly in high-pH or saline soils, and competing rootstocks like Swingle struggle in the poorly drained, heavy soils common on Florida's east coast and in the southwest of the state.
Soilcea's answer is Benicia D1, a CRISPR-edited version of US-812, a rootstock developed by USDA breeders that already outperforms Carrizo in the sandy, well-draining soils that define Florida's east coast citrus belt. Lagos has described the strategy explicitly as building out a portfolio matched to different soil types rather than betting the company on a single genetic background. UF Extension data backs the agronomic logic: US-812 has historically shown better juice quality characteristics than its closest rival, US-942, even before any disease-resistance editing was layered on top. If CarriCea T1 succeeds commercially on Carrizo's traditional ridge soils, Benicia D1 is positioned to capture the east coast acreage that Carrizo was never the right fit for in the first place, regardless of greening.
Soilcea's stated ambitions extend well past Florida. Lagos has said the company is already working with growers in Texas and is in talks with growers and researchers in California, framing the goal explicitly as a nationwide solution rather than a regional fix. That matters because greening is no longer a Florida-only problem; its confirmed spread into California, Texas, and six other states means the addressable market for an EPA-cleared, CRISPR-edited rootstock licensing model extends across most of the country's commercial citrus acreage.
There is a consumer-perception variable still in play. University of Florida food economists have been studying public acceptance of CRISPR-edited citrus separately from acceptance of older transgenic GMO approaches, and the distinction matters commercially: Florida's orange juice industry has spent years marketing a non-GMO label even though no commercial GMO citrus cultivar has ever actually been grown at scale. The EPA's own announcement anticipated the friction, stating explicitly that consumers preferring alternatives will continue to find organic citrus in the marketplace and that fruit from CarriCea T1 rootstock will be chemically indistinguishable from any other rootstock's fruit. Whether the gene-edited label proves to be a non-issue, as the science suggests it should, or a marketing headache the way "GMO" became for an earlier generation of biotech crops, is now a live commercial variable rather than a hypothetical one.
For an industry that has spent twenty years watching its core asset disappear at a rate of roughly 5 percent a year, the EPA's signature on April 28 did not solve the underlying disease. It did something narrower and more consequential for the people who actually own the land: it opened a window, finally, where planting decisions can be made on the assumption that the tools to fight back have caught up with the threat, rather than perpetually trailing behind it.